课题基金 / 基金详情

PILOT EVALUATION OF DAB-486 IL-2 ADMINISTERED TO PATIENTS WITH MALIGNANCIES

PILOT EVALUATION OF DAB-486 IL-2 ADMINISTERED TO PATIENTS WITH MALIGNANCIES
对恶性肿瘤患者施用 DAB-486 IL-2 的试点评估
批准号：
3784473
负责人：
TIMOTHY KUZEL
金额：
$0.0万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3784473
关键词：
antineoplastics dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation interleukin 2 intravenous administration neoplasm /cancer immunotherapy neoplasm /cancer pharmacology pharmacokinetics

项目摘要

项目成果

TIMOTHY KUZEL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study was to evaluate 1) the safety and tolerability of DAB-486 IL-2 when administered as a 60 minute infusion every 8 hours for 12 doses in escalating fashion; and 2) single and multiple dose pharmacokinetics and 3) the anti-tumor effects using this dose and schedule of DAB-486 IL-2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C3/C: Clinical Trials and Advocacy Core
Clinical Trials and Advocacy Core
NUY96H1--PHASE II TRIAL OF 9-AMINO CAMPOTHECIN IN CUTANEOUS T CELL LYMPHOMA
NUY96H1--PHASE II TRIAL OF 9-AMINO CAMPOTHECIN IN CUTANEOUS T CELL LYMPHOMA
海外基金